Status:
COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
Lead Sponsor:
Bristlecone Health, Inc.
Collaborating Sponsors:
University of Minnesota
Conditions:
Mild Cognitive Impairment
Metabolic Syndrome
Eligibility:
All Genders
35-80 years
Phase:
NA
Brief Summary
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corr...
Detailed Description
Nutritional epigenetics denotes gene-diet interactions and highlights the modulatory role of cellular energy status in aging and age-related diseases like cancer, cardiovascular disease (CVD), diabete...
Eligibility Criteria
Inclusion
- Male or Female (age 35-80)
- Previously diagnosed with MetS and/or T2DM as measured by possessing at least two of the following physiological measures: type 2 diabetes, BMI \> 30, HgA1c \> 5.7%, waist/height ratio \> .6, fasting glucose \> 125 mg/dL
- Subjective Memory Complaints (SCM) - Subjects score \> 3 'yes' answers on the Subjective Memory Complaints Questionnaire
- Previously diagnosed with Mild Cognitive Impairment (MCI)
Exclusion
- Previously diagnosed with Alzheimer's disease (AD), dementia or Parkinson's disease
Key Trial Info
Start Date :
October 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2018
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT03319173
Start Date
October 15 2017
End Date
September 30 2018
Last Update
November 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bristlecone Health, Inc.
Maple Grove, Minnesota, United States, 55311